EXANE DERIVATIVES - BRIDGEBIO PHARMA INC ownership

BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 182 filers reported holding BRIDGEBIO PHARMA INC in Q1 2022. The put-call ratio across all filers is 0.50 and the average weighting 0.3%.

Quarter-by-quarter ownership
EXANE DERIVATIVES ownership history of BRIDGEBIO PHARMA INC
ValueSharesWeighting
Q4 2021$54,141,000
-48.6%
3,246
+44.5%
0.01%
-48.0%
Q3 2021$105,313,000
-34.6%
2,247
-12.5%
0.02%
-32.4%
Q2 2021$161,087,000
+59.7%
2,568
+56.8%
0.04%
+27.6%
Q1 2021$100,896,000
+186.7%
1,638
+230.9%
0.03%
+190.0%
Q4 2020$35,198,0004950.01%
Other shareholders
BRIDGEBIO PHARMA INC shareholders Q1 2022
NameSharesValueWeighting ↓
Aisling Capital Management LP 3,835,722$103,449,00044.18%
Kohlberg Kravis Roberts & Co. L.P. 36,900,661$995,211,00012.26%
SC US (TTGP), LTD. 2,544,738$68,632,0004.69%
Cormorant Asset Management, LP 2,780,885$75,000,0004.31%
Perceptive Advisors 6,706,268$180,868,0004.15%
VIKING GLOBAL INVESTORS LP 26,620,991$717,968,0003.22%
Hillhouse Capital Management 2,035,790$54,905,0001.75%
Alpine Group USVI, LLC 20,000$539,0001.70%
HHLR ADVISORS, LTD. 2,352,900$63,458,0001.42%
SCGE MANAGEMENT, L.P. 588,235$15,865,0000.79%
View complete list of BRIDGEBIO PHARMA INC shareholders